CA-ARMIS
22.1.2024 14:01:31 CET | Business Wire | Press release
Armis, the asset intelligence cybersecurity company, today announced The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape. The 2023 analysis of Armis’ proprietary data offers critical insight into the multifaceted challenges global organizations face when it comes to protecting the entire attack surface. Report findings serve as a blueprint to help security teams worldwide prioritize efforts to reduce cyber risk exposure in 2024.
The report found that global attack attempts more than doubled in 2023, increasing 104%. Utilities (over 200% increase) and Manufacturing (165% increase) were the most at risk industries. Attack attempts peaked in July, with communications devices, imaging devices and manufacturing devices experiencing intensified targeting during this period.
“Armis found that not only are attack attempts increasing, but cybersecurity blind spots and critical vulnerabilities are worsening, painting prime targets for malicious actors,” said Nadir Izrael, CTO and Co-Founder, Armis. “It’s critical that security teams leverage similar intelligence defensively so that they know where to prioritize efforts and fill these gaps to mitigate risk. We hope that by sharing these insights, global businesses and governments will leverage them to immediately pinpoint what they should be focusing on to improve their cybersecurity posture this year to keep critical infrastructure, economies and society safe and secure.”
Key findings of The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape include:
Geopolitical tensions exacerbate the cybersecurity landscape
-
Cyberwarfare grew more widespread in 2023. Top industries exposed to attack from Chinese and Russian actors were those within Manufacturing, Educational Services and Public Administration.
- In manufacturing, .cn and .ru domains contributed to an average of 30% of monthly attack attempts, while attacks from these domains on Educational Services have risen to about 10% of total attacks.
Legacy technology steepens incline of cybersecurity pros’ existing up-hill battle
-
Older Windows server OS versions (2012 and earlier) are 77% more likely to experience attack attempts compared to newer Windows Server versions.
- This vulnerability is particularly evident in the server environment, with nearly a quarter of server versions facing end-of-support (EoS) scenarios. The Educational Services industry has a significantly higher percentage of servers (41%) with unpatched weaponized Common Vulnerabilities and Exposures (CVEs), compared to the general average of 10%.
- Industries still using end-of-life (EoL) or EoS OSs that are no longer actively supported or patched for vulnerabilities and security issues by the manufacturer: Educational Services (18%), Retail (14%), Healthcare (12%), Manufacturing (11%) and Public Administration (10%).
Businesses struggle with effective vulnerability prioritization and remediation
- There were over 65,000 unique CVEs discovered in 2023.
- Wearable devices have the highest percentage (93%) of unpatched CVEs.
- A third of all devices are still not patched for Log4Shell.
-
Patch rates for critical CVEs are not prioritized:
- Low CVEs: 11% patch rate
- Medium CVEs: 58% patch rate
- High CVEs: 64% patch rate
- Critical CVEs: 55% patch rate
- Irrespective of the weaponization status of a CVE, organizations consistently grapple with patch rates at 62% for non-weaponized and 61% for weaponized vulnerabilities.
“Blueprints like this report are invaluable as they help teams focus limited resources on efforts with the greatest impact and with the insights to tell data-driven stories in justification of cross-team priorities,” said Curtis Simpson, CISO, Armis. “Using hindsight and analyzed data could allow CISOs to focus 2024 efforts on segmenting legacy technology, prioritizing exposures of greatest significance, and utilizing AI-driven technologies that can assist security teams with defending and managing the attack surface in real-time.”
Proprietary data leveraged for this report was mined from Armis’ Asset Intelligence Engine. The Armis Asset Intelligence Engine is a collective AI-powered knowledge base, monitoring billions of assets worldwide, in order to identify cyber risk patterns and behaviors. It feeds the Armis Centrix™ platform with unique, actionable cyber intelligence to detect and address real-time threats across the entire attack surface.
To read the full report, The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape, please visit: https://www.armis.com/anatomy-of-cybersecurity
Learn more about The Armis Asset Intelligence Engine here: https://www.armis.com/platform/armis-asset-intelligence-engine/
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122998889/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
